Functional characterization of proximal promoter of gene for human BRAK/CXCL14, a tumor-suppressing chemokine

Biomedical Research

Volumn 31, Issue 2, 2010, Pages 123-131

  Komori, Reika ^a   Ozawa, Shigeyuki ^a   Kato, Yasumasa ^a   Shinji, Hisaaki ^a   Kimoto, Shigenari ^a   Hata, Ryu Ichiro ^a  

^a KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL14 CHEMOKINE; MESSENGER RNA; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN MOTIF; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SQUAMOUS EPITHELIUM; TRANSCRIPTION INITIATION SITE;

ANIMALS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CHEMOKINES; CHEMOKINES, CXC; DNA, COMPLEMENTARY; GENES, REPORTER; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1;

MUS; MUS MUSCULUS; PHOS;

EID: 77953290672     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.31.123     Document Type: Article

References (35)

1. Akai J, Kimura A and Hata RI (1999) Transcriptional regulation of the human type I collagen a2 (COL1A2) gene by the combination of two dinucleotide repeats. Gene 239, 65-73.
2. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR and Polyak K (2004) Molecular characteriz-tion of the tumor microenvironment in breast cancer. Cancer Cell 6, 17-32.
3. Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P. Levchenko T, Frederick MJ, Borg A Micke P, Egevad L and Ostman A (2009) CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106, 3414-3419.
4. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4, 540-550.
5. Bucher P (1990) Weight matrix descriptions of four eukary-otic RNA polymerase II promoter elements derived from 502 unrelated promoter sequences. J Mol Biol 212, 563-578.
6. Chiquet M, Mumenthaler U, Wittwer M, Jin W and Koch M (1998) The chick and human collagen al(XII) gene promo-er-activity of highly conserved regions around the first exon and in the first intron. Eur J Biochem 257, 362-371.
7. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P and Gray A (2003) The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and trans-membrane proteins: a bioinformatics assessment. Genome Res 13, 2265-2270.
8. Clausell A and Tucker PW (1994) Functional analysis of the V γ3 promoter of the murine γδT-cell receptor. Mol Cell Biol 14, 803-814.
9. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK and dayman GL (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156, 1937-1950.
10. Garcia-Moruja C, Alonso-Lobo JM, Rueda P, Torres C, Gonzalez N, Bermejo M, Luque F, Arenzana-Seisdedos F, Alcami J and Caruz A (2005) Functional characterization of SDF-1 proximal promoter. J Mol Biol 348, 43-62.
11. Gehringer MM (2004) Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response. FEBS Lett 557, 1-8.
12. Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christo-pherson K, 2nd, Azam M and Hou YH (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255, 703-706.
13. Kim HJ, Lee MH, Kim HJ, Shin HI, Choi JY and Ryoo HM (2002) Okadaic acid stimulates osteopontin expression through de novo induction of AP-1. J Cell Biochem 87, 93-102.
14. Martens JA and Brandl CJ (1994) GCN4p activation of the yeast TRP3 gene is enhanced by ABF1p and uses a subopti-mal TATA element. J Biol Chem 269, 15661-15667.
15. McKinnon CM, Lygoe KA, Skelton L, Mitter R and Mellor H (2008) The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells. Oncogene 27, 6856-6865.
16. Meuter S and Moser B (2008) Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cy-tokine 44, 248-255.
17. Milczarek GJ, Chen W, Gupta A, Martinez JD and Bowden GT (1999) Okadaic acid mediates p53 hyperphosphorylation and growth arrest in cells with wild-type p53 but increases aberrant mitoses in cells with non-functional p53. Carcino-genesis 20, 1043-1048.
18. Otsuki T, Ota T, Nishikawa T, Hayashi K, Suzuki Y, Yamamoto J, Wakamatsu A, Kimura K, Sakamoto K, Hatano N, Kawai Y, Ishii S, Saito K, Kojima S, Sugiyama T, Ono T, Okano K, Yoshikawa Y, Aotsuka S, Sasaki N, Hattori A, Okumura K, Nagai K, Sugano S and Isogai T (2005) Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries. DNA Res 12, 117-126.
19. Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Kubota E and Hata RI (2009) Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squa-mous cell carcinoma. Cancer Sci 100, 2202-2209.
20. Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E and Hata R (2006) BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun 348, 406-112.
21. Ozawa S, Kato Y, Kubota E and Hata R (2009) BRAK/ CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse. Biomed Res 30, 315-318.
22. Rollins BJ (2006) Inflammatory chemokines in cancer growth and progression. Eur J Cancer 42, 760-767.
23. Ross S, Tienhaara A, Lee MS, Tsai LH and Gill G (2002) GC box-binding transcription factors control the neuron specific transcription of the cyclin-dependent kinase 5 regulator p35. J Biol Chem 277, 4455-4464.
24. Schwarze SR, Luo J, Isaacs WB and Jarrard DF (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64, 67-74
25. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D, Clayman GL and Frederick MJ (2004) BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64, 8262-8270.
26. Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, Collins B, Chatta GS and Shurin MR (2005) Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 174, 5490-5498.
27. Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, Watson JD and Kumble KD (2000) B cell-and monocyte-activating chemokine (BMAC), a novel non-ELR α-chemokine. Int Immunol 12, 677-689.
28. Thompson EJ, MacGowan J, Young MR, Colburn N and Bowden GT (2002) A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res 62, 3044-3047.
29. Weis L and Reinberg D (1997) Accurate positioning of RNA polymerase II on a natural TATA-less promoter is independent of TATA-binding-protein-associated factors and initiator-binding proteins. Mol Cell Biol 17, 2973-2984.
30. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Büchler MW and Friess H (2008) CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 259, 209-217.
31. Yang C, Bolotin E, Jiang T, Sladek FM and Martinez E (2007) Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. Gene 389, 52-65.
32. Yatsunami J, Komori A, Ohta T, Suganuma M and Fujiki H (1993) Hyperphosphorylation of retinoblastoma protein and p53 by okadaic acid, a tumor promoter. Cancer Res 53, 239-241.
33. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Ap-pella E, Oppenheim JJ and Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cyto-kines. Proc Natl Acad Sci USA 84, 9233-9237.
34. Zlotnik A (2006) Chemokines and cancer. Int J Cancer 119, 2026-2029.
35. Zlotnik A and Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127